AUTHOR=Marques-Pamies Montserrat , Gil Joan , Valassi Elena , Hernández Marta , Biagetti Betina , Giménez-Palop Olga , Martínez Silvia , Carrato Cristina , Pons Laura , Villar-Taibo Rocío , Araujo-Castro Marta , Blanco Concepción , Simón Inmaculada , Simó-Servat Andreu , Xifra Gemma , Vázquez Federico , Pavón Isabel , García-Centeno Rogelio , Zavala Roxana , Hanzu Felicia Alexandra , Mora Mireia , Aulinas Anna , Vilarrasa Nuria , Librizzi Soledad , Calatayud María , de Miguel Paz , Alvarez-Escola Cristina , Picó Antonio , Sampedro Miguel , Salinas Isabel , Fajardo-Montañana Carmen , Cámara Rosa , Bernabéu Ignacio , Jordà Mireia , Webb Susan M. , Marazuela Mónica , Puig-Domingo Manel 

TITLE=Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1269787

DOI=10.3389/fendo.2023.1269787

ISSN=1664-2392

ABSTRACT=Patients with E-cadherin positive tumors showed a lower GH2h than those negative [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01] and patients with positive E-cadherin presented a higher score of SSTR2 (7.5±4.2 vs 3.3±2.1; p=0.01). CONCLUSIONS: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in acromegalic patients.Prediction tools to assess response to medical treatment in acromegaly are necessary. The short version of the acute octreotide test is an easy, inexpensive, and sufficiently informative test that can help the clinician to identify responsiveness to SRLs in acromegaly.1.